BIOLARGO, INC. issued 500,000 shares of common stock to CLEARTHINK CAPITAL PARTNERS, LLC.
“we agreed to issue Clearthink 500,000 shares of our Common Stock (the “Commitment Shares”) upon the execution of the Purchase Agreement.”
BIOLARGO, INC. — fact timeline
Source-grounded facts extracted from BIOLARGO, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIOLARGO, INC. entered into Purchase Agreement with CLEARTHINK CAPITAL PARTNERS, LLC valued at up to $10.0 million (effective 2026-03-20).
“On March 20, 2026, BioLargo, Inc. (the “Company” or “we”) entered into a purchase agreement dated as of March 20, 2026 (the “Purchase Agreement”), and a registration rights agreement dated as of March 20, 2026 (the “Registration Rights Agreement”), with CLEARTHINK CAPITAL PARTNERS, LLC (“Clearthink”), pursuant to which Clearthink has committed to purchase up to $10.0 million of the Company’s common stock”
BIOLARGO, INC. engaged Hacker Johnson & Smith PA as its auditor.
“approved the engagement of Hacker Johnson & Smith PA ("Hacker Johnson") as the Company's independent registered public accounting firm”
BIOLARGO, INC. dismissed Haskell & White LLP as its auditor.
“dismissed Haskell & White LLP ("Haskell & White"), as the Company's independent registered public accounting firm.”
BIOLARGO, INC. shareholders approved To ratify the appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-06 meeting.
“3 (Auditors) 155,955,456 2,327,659 942,810 - 98.5%”
BIOLARGO, INC. shareholders approved To approve, on an advisory basis, the compensation of the Company’s named executive officers at the 2023-06-06 meeting.
“2 (Exec Comp) 76,470,107 5,477,240 2,816,330 74,462,248 93.3%”
BIOLARGO, INC. shareholders approved Election of seven directors to the Board at the 2023-06-06 meeting.
“Each director was elected to the Company’s Board of Directors, and each of proposal 2 and 3 was approved, in accordance with Delaware law and the Company’s bylaws. The voting results are as follows: Proposal One Votes For Votes Withheld Broker Non-Vote Dennis P. Calvert 80,555,622 4,208,055 74,462,248 Kenneth R. Code 82,050,224 2,713,453 74,462,248 Dennis E. Marshall 82,044,744 2,718,933 74,462,248 Joseph L. Provenzano 81,922,025 2,841,652 74,462,248 Jack B. Strommen 82,074,224 2,689,453 74,462,248 Linda Park 82,733,837 2,029,840 74,462,248 Christina Bray 82,733,837 2,029,840 74,462,248”
BIOLARGO, INC. entered into Registration Rights Agreement with Lincoln Park Capital Fund, LLC (effective 2022-12-12).
“On December 13, 2022, BioLargo, Inc. (the “Company” or “we”) entered into a purchase agreement, dated as of December 13, 2022 (the “Purchase Agreement”), and a registration rights agreement, dated as of December 12, 2022 (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”)”
BIOLARGO, INC. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $10.0 million (effective 2022-12-13).
“On December 13, 2022, BioLargo, Inc. (the “Company” or “we”) entered into a purchase agreement, dated as of December 13, 2022 (the “Purchase Agreement”), and a registration rights agreement, dated as of December 12, 2022 (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $10.0 million of the Company’s common stock”
Christina Bray was appointed as Director at BIOLARGO, INC..
“appointed Linda Park and Christina Bray to the board”
Linda Park was appointed as Director at BIOLARGO, INC..
“appointed Linda Park and Christina Bray to the board”
Kent C. Roberts II resigned as Director at BIOLARGO, INC..
“accepted the resignations of board members John S. Runyan and Kent C. Roberts II”
John S. Runyan resigned as Director at BIOLARGO, INC..
“accepted the resignations of board members John S. Runyan and Kent C. Roberts II”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.